Lenvatinib (E7080)

製品コードS1164

Lenvatinib (E7080)化学構造

分子量(MW):426.85

Lenvatinib (E7080)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR2(KDR)/VEGFR3(Flt-4)に作用する効果が一番強くて、IC50値が4 nM/5.2 nM,になることです。Lenvatinib (E7080)はVEGFR1/Flt-1に作用する効果が少し弱くて、VEGFR2/3に作用する選択性はFGFR1とPDGFRα/βに作用する選択性より10倍左右がそれぞれ高くなります。臨床3期。

サイズ 価格(税別) 在庫  
JPY 49800.00 あり
JPY 11620.00 あり
JPY 24900.00 あり
JPY 44820.00 あり
JPY 127820.00 あり

カスタマーフィードバック(4)

  • Dot Plot Distribution of Live, Preapoptotic and Apoptotic Cells after Administration of DuP-697 and E7080 Combination.

    Asian Pac J Cancer Prev 2014 15(7), 3113-21. Lenvatinib (E7080) purchased from Selleck.

    Inhibitors of tyrosine kinase receptor suppressed the in vitro angiogenesis of HUVECs. The angiogenesis of HUVECs was evaluated in the absence (control in A) or presence of CP-673451 (5 nM), a selective inhibitor of PDGFR or E7080 (50 nM), an active inhibitor for multiple tyrosine kinase receptors for 6 h. The two agents only inhibit the kinase activity of the relative tyrosine kinase receptors, but do not cause a toxic effect to the cells in the concentration used in this study (Roberts et al., 2005 ; Wiegering et al., 2014). For quantification, the values for the pattern recognition, branch point and total capillary tube length are described in the Methods section. Representative microscopic fields are shown in Panel A. The suppressive effects of the inhibitors on angiogenesis of HUVECs are shown in B, C and D. The data are expressed relative to that of the control cells without exposure to the inhibitor. N = 5, *P < 0.05 and **P < 0.01 versus the control cells.

    Environ Toxicol Pharmacol, 2016, 46:168-73. Lenvatinib (E7080) purchased from Selleck.

  • Real-time monitoring of cytotoxic effect on HT29 cells using RTCA. (A) E7080

    Chin J Cancer Res 2013 25(5), 572-84. Lenvatinib (E7080) purchased from Selleck.

    Calculation of IC50 of E7080 (IC50 =5.60×10–8 mol/L, square R =0.998).

    Chin J Cancer Res 2013 25(5), 572-84. Lenvatinib (E7080) purchased from Selleck.

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Lenvatinib (E7080)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR2(KDR)/VEGFR3(Flt-4)に作用する効果が一番強くて、IC50値が4 nM/5.2 nM,になることです。Lenvatinib (E7080)はVEGFR1/Flt-1に作用する効果が少し弱くて、VEGFR2/3に作用する選択性はFGFR1とPDGFRα/βに作用する選択性より10倍左右がそれぞれ高くなります。臨床3期。
ターゲット
VEGFR2/KDR [1]
(Cell-free assay)
VEGFR3/FLT4 [1]
(Cell-free assay)
VEGFR1/FLT1 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
FGFR1 [1]
(Cell-free assay)
4.0 nM 5.2 nM 22 nM 39 nM 46 nM
体外試験

E7080, as a potent inhibitor of in vitro angiogenesis, shows a significantly inhibitory effect on VEGF/KDR and SCF/Kit signaling. According to the in vitro receptor tyrosine and serine/threonine kinase assays, E7080 inhibits Flt-1, KDR, Flt-4 with IC50 of 22, 4.0 and 5.2 nM, respectively. In addition to these kinases, E7080 also inhibits FGFR1 and PDGFR tyrosine kinases with IC50 value of 46, 51 and 100 nM for FGFR1, PDGFRα and PDGFRβ, respectively. [1] E7080 potently inhibits phosphorylation of VEGFR2 (IC50, 0.83 nM) and VEGFR3 (IC50, 0.36 nM) in HUVECs which is stimulated by VEGF and VEGF-C, respectively. [2] A recent study shows that E7080 treatment (both at 1 μM and 10 μM) results in a significant inhibition of cell migration and invasion by inhibiting FGFR and PDGFR signaling. [3]

体内試験 When orally administrated in a H146 xenograft model, E7080 inhibits the growth of H146 tumor at 30 and 100 mg/kg in a dose-dependent manner and leads to tumor regression at 100 mg/kg. Furthermore, E7080 at 100 mg/kg decreases microvessel density more than anti-VEGF antibody and imatinib treatment. [1] E7080 significantly inhibits local tumor growth in a MDA-MB-231 mammary fat pad (m.f.p.) model with RTVs (calculated tumor volume on day 8/tumor volume on day 1) of 0.81, and reduces both angiogenesis and lymphangiogenesis of established metastatic nodules of MDA-MB-231 tumor in the lymph nodes. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

In vitro kinase assay [1]:

Tyrosine kinase assays are performed by HTRF (KDR, VEGFR1, FGFR1, c-Met, EGFR) and ELISA (PDGFRβ), using the recombinant kinase domains of receptors. In both assays, 4 μL of serial dilutions of E7080 are mixed in a 96-well round plate with 10 μL of enzyme, 16 μL of poly (GT) solution (250 ng) and 10 μL of ATP solution (1 μM ATP) (final concentration of DMSO is 0.1%). In wells for blanks, no enzyme is added. In control wells no test article is added. The kinase reaction is initiated by adding ATP solution to each well. After 30-minute incubation at 30°C, the reaction is stopped by adding 0.5 M EDTA (10 μL/well) to the reaction mixture in each well. Dilution buffer adequate to each kinase assay is added to the reaction mixture. In the HTRF assay, 50 μL of the reaction mixture is transferred to a 96-well 1/2 area black EIA/RIA plate, HTRF solution (50 μL/well) is added to the reaction mixture, and then kinase activity is determined by measurement of fluorescence with a time-resolved fluorescence detector at an excitation wavelength of 337 nm and an emission wavelengths of 620 and 665 nm. In the ELISA, 50 μL of the reaction mixture is incubated in avidin coated 96-well polystyrene plates at room temperature for 30 minutes. After washing with wash buffer, PY20-HRP solution (70 μL/well) is added and the reaction mixture is incubated at room temperature for 30 minutes. After washing with wash buffer, TMB reagent (100 μL/well) is added to each well. After several minutes (10–30 minutes), 1 M H3PO4 (100 μL/well) is added to each well. Kinase activity is determined by measurement of absorbance at 450 nm with a microplate reader.
細胞試験: [2]
+ 展開
  • 細胞株: HUVECs
  • 濃度: 0-10 μM
  • 反応時間: 72 hours
  • 実験の流れ: HUVECs (1,000 cells in each well in serum-free medium containing 2% fetal bovine serum) and L6 rat skeletal muscle myoblasts (5,000 cells in each well in serum-free DMEM) are dispensed in a 96-well plate and incubated overnight. E7080 and either VEGF (20 ng/mL) or FGF-2 (20 ng/mL) containing 2% fetal bovine serum and PDGFβ (40 ng/mL) are added to each well. Cells are incubated for 3 days and then the ratios of surviving cells are measured by WST-1 reagent. For proliferation assay, samples are duplicated and three separate experiments are done.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: H146 tumor cells are implanted subcutaneously (s.c.) into the flank region of female BALB/c nude mice.
  • 製剤: E7080 is dissolved in suspended in 0.5% methylcellulose.
  • 投薬量: ≤100 mg/kg
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 40 mg/mL (93.7 mM) warming
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
0.5% methylcellulose
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 426.85
化学式

C21H19ClN4O4

CAS No. 417716-92-8
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02657369 Recruiting Thyroid Cancer, Anaplastic Eisai Inc. July 7, 2016 Phase 2
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02788708 Recruiting Fallopian Tube Carcinoma|Recurrent Ovarian Cancer|Primary Peritoneal Carcinoma|Recurrent Endometrial Cancer Floor Backes|Eisai Inc.|Ohio State University Comprehensive Cancer Center May 27, 2016 Phase 1
NCT02501096 Recruiting Tumors Eisai Inc. July 22, 2015 Phase 1|Phase 2
NCT03009292 Not yet recruiting Solid Tumor Eisai Inc. January 2019 Phase 1
NCT02973997 Not yet recruiting Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma|Stage IVA Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Differentiated Thyroid Gland Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) April 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

VEGFR信号経路図

VEGFR Inhibitors with Unique Features

相関VEGFR製品

Tags: Lenvatinib (E7080)を買う | Lenvatinib (E7080) ic50 | Lenvatinib (E7080)供給者 | Lenvatinib (E7080)を購入する | Lenvatinib (E7080)費用 | Lenvatinib (E7080)生産者 | オーダーLenvatinib (E7080) | Lenvatinib (E7080)化学構造 | Lenvatinib (E7080)分子量 | Lenvatinib (E7080)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID